Amphia Hospital

At Amphia Hospital in Breda, the Hematology department is running clinical trials focused on hemic and lymphatic diseases and neoplasms. The studies are centered on major blood cancers and related disorders, with the goal of improving treatment effectiveness and long-term outcomes for patients.

• Research in acute myeloid leukemia and myelodysplastic syndrome explores new treatment combinations for patients with specific genetic mutations.
• Trials in relapsed or refractory multiple myeloma are evaluating whether newer therapy options can better control disease progression.
• Studies in high risk diffuse large B-cell lymphoma are assessing consolidation treatment strategies to improve remission durability.

This research environment reflects a strong focus on testing more effective therapies for complex hematologic malignancies, especially where standard treatment options may be limited.

Clinical research at this site also includes oncology studies for solid tumors, with attention to treatments for metastatic castration-resistant prostate cancer and renal cell carcinoma. These trials aim to determine whether new treatment approaches can improve survival and delay disease progression.

• In prostate cancer, studies are comparing treatment approaches to see which better supports overall survival and disease control.
• In renal cell carcinoma, research is examining adjuvant treatment options after surgery to reduce the chance of recurrence.

The work at Amphia Hospital highlights efforts to refine cancer care across both advanced and post-surgical settings.

A key area of research involves leukemia trials designed around specific genetic changes, including IDH1, IDH2, and FLT3 mutations. These studies are focused on finding better ways to guide treatment selection and improve outcomes in newly diagnosed disease.

• Trials in acute myeloid leukemia are evaluating targeted treatment strategies alongside standard chemotherapy.
• Research in MDS-EB2 is examining whether mutation-directed therapy can strengthen disease control.
• The main purpose is to test whether personalized treatment can improve event-free survival and reduce relapse risk.

This line of research supports more individualized care for patients with aggressive blood cancers.

The site is also involved in clinical trials for diffuse large B-cell lymphoma and multiple myeloma, two important areas within hematologic oncology. These studies are designed to improve disease control after initial therapy and in cases where the cancer has returned or is no longer responding well.

• In high risk diffuse large B-cell lymphoma, researchers are assessing whether consolidation treatment can help maintain remission.
• In relapsed or refractory multiple myeloma, trials are comparing combinations intended to improve progression-free survival.

Together, these studies show a broad effort to strengthen treatment options for difficult-to-treat hematologic cancers.